抗肿瘤新药碳铂(卡铂)临床前毒理学研究及其临床运用

来源 :浙江肿瘤通讯 | 被引量 : 0次 | 上传用户:xiaoping123123
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
碳铂(卡铂,Carhoplatin,CBDCA,JM-8,NSC241240,Paraplatin)是继顺铂(Cisplatin)之后第二代铂类抗肿瘤新药。英国86年批准生产,90年我国批准生产。顺铂自七十年代初问世以来,很快被公认为抗癌谱广,疗效高的抗癌药物特别是对乏氧细胞也有作用,在很多联合化疗中占有重要地位。但是它的毒性大,特别是对肾脏有 Carboplatin (Carboplatin, Carboplatin, CBDCA, JM-8, NSC241240, Paraplatin) is the second-generation platinum antitumor drug following Cisplatin. The United Kingdom approved production in 86 years, and China approved production in 90 years. Since its inception in the early seventies, cisplatin was quickly recognized as an anticancer drug with a broad spectrum of anti-cancer effects. It has an effect on hypoxic cells, and plays an important role in many combinations of chemotherapy. But its toxicity is great, especially for the kidneys
其他文献